Cassava Sciences INC (FLNA) — 8-K Filings

All 8-K filings from Cassava Sciences INC. Browse 39 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (39)

8-K Filing — Dec 23, 2025
8-K Filing — Dec 18, 2025
Cassava Sciences Files 8-K on Director Changes — Dec 17, 2025 Risk: medium
On December 12, 2025, Cassava Sciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates th
Cassava Sciences Files 8-K Report — Dec 3, 2025 Risk: medium
On November 26, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing indicates that the company is providing information under 'Other Events'. Specific
Cassava Sciences Files 8-K on Operations and Finances — Nov 12, 2025 Risk: low
Cassava Sciences, Inc. filed an 8-K on November 12, 2025, reporting on its results of operations and financial condition, as well as submitting financial statem
Cassava Sciences Files 8-K Report — Oct 24, 2025 Risk: medium
On October 23, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not pro
Cassava Sciences Files 8-K: Director Changes & Compensation Updates — Oct 22, 2025 Risk: medium
On October 21, 2025, Cassava Sciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the
Cassava Sciences Files 8-K with Corporate Updates — Sep 8, 2025 Risk: low
Cassava Sciences, Inc. filed an 8-K on September 8, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
Cassava Sciences Files 8-K on Financials — Aug 14, 2025 Risk: low
Cassava Sciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition, and including financial statements and e
Cassava Sciences Files 8-K with Regulatory Updates — Aug 4, 2025 Risk: medium
Cassava Sciences, Inc. filed an 8-K on August 4, 2025, reporting on various events. The filing includes information on Regulation FD disclosures, other events,
Cassava Sciences Files 8-K: Regulation FD & Exhibits — Jun 30, 2025 Risk: low
On June 30, 2025, Cassava Sciences, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly k
Cassava Sciences Files 8-K: Director Changes, Shareholder Votes, Financials — May 27, 2025 Risk: medium
Cassava Sciences, Inc. filed an 8-K on May 27, 2025, reporting events as of May 23, 2025. The filing indicates changes related to directors and officers, the su
Cassava Sciences Files 8-K on Financials — May 8, 2025 Risk: medium
Cassava Sciences, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as presenting financial statements a
Cassava Sciences: Director Departs, New CMO Elected — Apr 21, 2025 Risk: medium
On April 15, 2025, Cassava Sciences, Inc. filed an 8-K report detailing the departure of Dr. James M. Gill as a director, effective April 15, 2025. The filing a
Cassava Sciences Files 8-K Report — Mar 25, 2025 Risk: low
On March 25, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
Cassava Sciences Shuffles Top Medical and Scientific Roles — Mar 11, 2025 Risk: medium
On March 6, 2025, Cassava Sciences, Inc. filed an 8-K report detailing the departure of Dr. Feng-Joon (Frank) Chen from his roles as Chief Medical Officer and C
Cassava Sciences Files 8-K on Financials — Mar 3, 2025 Risk: medium
Cassava Sciences, Inc. filed an 8-K on March 3, 2025, reporting on its results of operations and financial condition, and also including financial statements an
Cassava Sciences Files 8-K: Material Agreement & Disclosures — Feb 27, 2025 Risk: medium
Cassava Sciences, Inc. filed an 8-K on February 27, 2025, reporting on a material definitive agreement and Regulation FD disclosure. The filing also includes fi
Cassava Sciences Files 8-K on Operations and Financials — Jan 7, 2025 Risk: medium
On January 7, 2025, Cassava Sciences, Inc. filed an 8-K report detailing significant events. The filing indicates the company is reporting on its results of ope
Cassava Sciences Files 8-K — Nov 25, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on November 25, 2024, reporting other events and financial statements. The company, previously known as Pain Therapeutics In
Cassava Sciences Files 8-K on Financials — Nov 7, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as submitting financial stateme
Cassava Sciences Files 8-K — Oct 8, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on October 8, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
Cassava Sciences Files 8-K — Sep 27, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on September 27, 2024, reporting on events as of September 26, 2024. The filing primarily concerns Regulation FD Disclosure,
Cassava Sciences Files 8-K for Financials — Sep 17, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on September 17, 2024, reporting an event that occurred on September 13, 2024. The filing is primarily for financial stateme
Cassava Sciences Board Shake-up: New Director Appointed, One Departs — Sep 9, 2024 Risk: medium
Cassava Sciences, Inc. announced on September 6, 2024, a change in its board of directors. Specifically, Dr. James M. Kuo has resigned from his position as a di
Cassava Sciences Files 8-K on Financials and Listing Status — Aug 8, 2024 Risk: medium
Cassava Sciences, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing also addresses a notice of del
Cassava Sciences Files 8-K — Jul 22, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on July 22, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
Cassava Sciences Issues Shares from Warrant Exercise — Jul 18, 2024 Risk: low
On July 18, 2024, Cassava Sciences, Inc. filed an 8-K report detailing the issuance of 1,111,111 shares of common stock upon the exercise of warrants. This resu
Cassava Sciences Files 8-K: Director Changes & Officer Compensation Updates — Jul 17, 2024 Risk: medium
On July 15, 2024, Cassava Sciences, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new direct
Cassava Sciences Updates Business Address — Jul 1, 2024 Risk: low
On July 1, 2024, Cassava Sciences, Inc. filed an 8-K report. The filing indicates a change in the company's business address to 6801 N Capital of Texas Highway,
Cassava Sciences Appoints New CMO, Adds Directors — May 22, 2024 Risk: medium
Cassava Sciences, Inc. announced on May 20, 2024, the appointment of Dr. Sanford D. Greenberg as Chief Medical Officer and the election of Ms. Mary Ann Gray and
Cassava Sciences Files 8-K on Shareholder Votes and Financials — May 13, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on May 13, 2024, reporting on matters submitted to a vote of security holders and financial statements as of May 9, 2024. Th
Cassava Sciences Files 8-K on Financials — May 10, 2024 Risk: low
On May 10, 2024, Cassava Sciences, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is involved i
Cassava Sciences Appoints New Chief Medical Officer — May 8, 2024 Risk: medium
On May 8, 2024, Cassava Sciences, Inc. filed an 8-K report detailing the appointment of Dr. Eric D. Newman as Chief Medical Officer. Dr. Newman brings extensive
Cassava Sciences Files 8-K — May 1, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on May 1, 2024, to report other events and financial statements. The filing does not contain specific financial figures or d
Cassava Sciences Files 8-K — Apr 15, 2024 Risk: low
Cassava Sciences, Inc. filed an 8-K on April 15, 2024, reporting other events and financial statements. The company, previously known as Pain Therapeutics Inc.,
Cassava Sciences Files 8-K on Financial Condition — Feb 28, 2024 Risk: medium
Cassava Sciences, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates that the company,
Cassava Sciences Files Routine 8-K, Confirms NASDAQ Listing — Feb 7, 2024
Cassava Sciences, Inc. filed an 8-K on February 7, 2024, to update its registration information, specifically noting its Common Stock, $0.001 par value, is regi
Cassava Sciences Reports Material Definitive Agreement on Jan 3 — Jan 3, 2024
Cassava Sciences, Inc. filed an 8-K on January 3, 2024, to report an "Entry into a Material Definitive Agreement" and "Financial Statements and Exhibits." This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX